Press release
Renal Cell Carcinoma Market Is Expected to Rise at a Healthy Growth Rate During the Forecast Period | Exelixis, ColImmune, MedImmune LLC, CRISPR Therapeutics, Merck, Daiichi Sankyo
Renal Cell Carcinoma Market
DelveInsight's "Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast 2032 [https://www.delveinsight.com/report-store/renal-cell-carcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Renal Cell Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Renal Cell Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Renal Cell Carcinoma Overview
Renal cell carcinoma is the most common type of kidney cancer, originating in the lining of the proximal convoluted tubule, which is a part of the small tubes in the kidney that transport waste molecules from the blood to the urine.
Renal Cell Carcinoma Market [https://www.delveinsight.com/report-store/renal-cell-carcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Renal Cell Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
DelveInsight's assessment reveals that in 2021, there were 138,000 incident cases of renal cell carcinoma across the seven major markets, with the highest number observed in the United States. It is anticipated that these cases will continue to increase by 2032.
Renal Cell Carcinoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Renal Cell Carcinoma Epidemiology, Segmented as -
*
Incident Cases of RCC (2019-2032)
*
Stage-specific Diagnosed Incident Cases of RCC (2019-2032)
*
Incident Cases of Kidney Cancer (2019-2032)
*
Gender-specific Diagnosed Incident of RCC (2019-2032)
*
Subtype-specific Diagnosed Incident of RCC (2019-2032)
*
Advanced RCC Progression from Localized to Advanced RCC (2019-2032)
Renal Cell Carcinoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Renal Cell Carcinoma market or expected to be launched during the study period. The analysis covers the Renal Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Renal Cell Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Renal Cell Carcinoma Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/renal-cell-carcinoma-market [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Renal Cell Carcinoma Treatment Analysis [https://www.delveinsight.com/report-store/renal-cell-carcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
The landscape of renal cell carcinoma (RCC) treatment has been transformed by the approvals of nivolumab, cabozantinib, and lenvatinib/everolimus. However, systemic therapy options for non-clear cell RCC remain limited. Promising preliminary results from immunotherapy are under investigation, while personalized treatments targeting specific genomic changes in tumors are driving future biomarker-based research.
For advanced clear-cell RCC, future therapeutic approaches include the development of new kinase inhibitors, repurposing existing drugs for new indications, and combining checkpoint inhibitors with targeted therapies. Treatment decisions for RCC are based on cancer stage and type, with multiple options available depending on these factors.
In November 2021, the USFDA approved Keytruda (pembrolizumab) for adjuvant treatment of RCC in patients at intermediate-high or high risk of recurrence post-nephrectomy, with or without resection of metastatic lesions. Keytruda is a selective humanized monoclonal IgG4 antibody targeting the PD-1 receptor on cell surfaces. By inhibiting PD-1, it prevents the binding and activation of PD-L1 and PD-L2, thereby activating T-cell-mediated immune responses against tumor cells.
Several other drugs have received FDA approval for RCC treatment, including Afinitor (everolimus), aldesleukin, bevacizumab, avelumab, Fotivda (tivozanib hydrochloride), IL-2 (aldesleukin), ipilimumab, Nexavar (sorafenib tosylate), Sunitinib malate, Welireg (belzutifan), and Yervoy (ipilimumab). These medications contribute to the expanding arsenal of treatments available for managing RCC across different stages and types.
Leading Companies in the Renal cell carcinoma Therapeutics Market Include Akesobio, Allogene Therapeutics, Amgen, Aravivie Inc, AstraZeneca, Aveao pharmaceuticals, Bayer Healthcare, Betta Pharmaceuticals, Bristol-Myers Squibb, Cemiplimab, Chia Tai Tianqing Pharmaceutical, ColImmune, Corvus Pharmaceuticals, CRISPR Therapeutics, GlaxoSmithKline, Hoffman La Roche, Incyte Corporation, Infinity Pharmaceuticals, Ipsen, Merck Sharp & Dohme Corp., Novartis, Pfizer, Regeneron Pharmaceuticals, X4 pharmaceuticals, and many others.
Renal Cell Carcinoma Emerging and Marketed Drugs Profile:
*
AK104 Plus Axitinib: Akesobio
*
ALLO-316: Allogene Therapeutics
*
Ciforadenant: Corvus Pharmaceuticals
*
CM082: Betta Pharmaceuticals
*
CMN-001: ColImmune
*
CTX130: CRISPR Therapeutics
*
IPI-549: Infinity Pharmaceuticals
*
TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/renal-cell-carcinoma-market [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Key Insights
2. Executive Summary
3. Renal Cell Carcinoma Competitive Intelligence Analysis
4. Renal Cell Carcinoma Market Overview at a Glance
5. Renal Cell Carcinoma Disease Background and Overview
6. Renal Cell Carcinoma Patient Journey
7. Renal Cell Carcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Renal Cell Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Renal Cell Carcinoma Unmet Needs
10. Key Endpoints of Renal Cell Carcinoma Treatment
11. Renal Cell Carcinoma Marketed Products
12. Renal Cell Carcinoma Emerging Drugs and Latest Therapeutic Advances
13. Renal Cell Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Renal Cell Carcinoma Market Outlook (In US, EU5, and Japan)
16. Renal Cell Carcinoma Access and Reimbursement Overview
17. KOL Views on the Renal Cell Carcinoma Market
18. Renal Cell Carcinoma Market Drivers
19. Renal Cell Carcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=renal-cell-carcinoma-market-is-expected-to-rise-at-a-healthy-growth-rate-during-the-forecast-period-exelixis-colimmune-medimmune-llc-crispr-therapeutics-merck-daiichi-sankyo]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Cell Carcinoma Market Is Expected to Rise at a Healthy Growth Rate During the Forecast Period | Exelixis, ColImmune, MedImmune LLC, CRISPR Therapeutics, Merck, Daiichi Sankyo here
News-ID: 3542090 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
